519173-11-6

Basic information

• Product Name: 4-(5-Chloro-2-Hydroxy-Phenyl)-4-Oxo-Butyronitrile
• Synonyms: 4-(5-Chloro-2-Hydroxy-Phenyl)-4-Oxo-Butyronitrile
• CAS NO: 519173-11-6
• Molecular Weight: 209.632
• Mol File: 519173-11-6.mol

Chemical Properties

• CAS DataBase Reference: 4-(5-Chloro-2-Hydroxy-Phenyl)-4-Oxo-Butyronitrile(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(5-Chloro-2-Hydroxy-Phenyl)-4-Oxo-Butyronitrile(519173-11-6)
• EPA Substance Registry System: 4-(5-Chloro-2-Hydroxy-Phenyl)-4-Oxo-Butyronitrile(519173-11-6)

Safety Data

• Hazardous Substances Data: 519173-11-6(Hazardous Substances Data)

Upstream product

• 1450-74-4 5-chloro-2-hydroxyacetophenone 
• 14171-36-9 methyl magnesium carbonate 
• 590-17-0 cyanomethyl bromide 

Downstream Products

• 519173-12-7 4-(5-Chloro-2-{2-[4-(4-Fluoro-Benzyl)-(2R,5S)-2,5-Dimethyl-Piperazin-1-Yl]-2-Oxo-Ethoxy}-Phenyl)-4-Oxo-Butyronitrile 

Relevant articles and documents

Methods of using piperazine derivatives

The present invention relates to compounds of the formula I and the pharmaceutically acceptable forms thereof; wherein X, Y, a, b, c, d, R1, R2, R3, R4 and R5 are as defined herein. Moreover, the present invention is also directed at pharmaceutical compositions comprising a compound of the formula I and a pharmaceutically acceptable carrier. Furthermore, the present invention is directed at methods of using the herein described compounds and compositions for treating or preventing a disorder or condition that can be treated or prevented by antagonizing the CCR1 receptor in a mammal.

Inhibition of p38 kinase using symmetrical and unsymmetrical diphenyl ureas

This invention relates to the use of a group of aryl ureas in treating cytokine mediated diseases and proteolytic enzyme mediated diseases, and pharmaceutical compositions for use in such therapy.